Oric Pharmaceuticals Inc. (ORIC): Price and Financial Metrics
ORIC Price/Volume Stats
| Current price | $8.27 | 52-week high | $9.79 |
| Prev. close | $7.90 | 52-week low | $2.91 |
| Day low | $7.65 | Volume | 412,500 |
| Day high | $8.30 | Avg. volume | 339,533 |
| 50-day MA | $6.52 | Dividend yield | N/A |
| 200-day MA | $6.49 | Market Cap | 451.14M |
ORIC Stock Price Chart Interactive Chart >
Oric Pharmaceuticals Inc. (ORIC) Company Bio
Oric Pharmaceuticals, Inc. is a clinical stage company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Latest ORIC News From Around the Web
Below are the latest news stories about ORIC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ORIC as an investment opportunity.
ORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in November: Jefferies London Healthcare Conference – Participating in a fireside chat on Thursday, November 16, 2023, at 10:00 a.m. GMT6th Annual Evercore ISI HealthCONx Conference – |
ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational UpdatesORIC's Cash and Investments Reach $256.2 Million, R&D Expenses Increase to $22.4 Million |
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesPresented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile Initial Phase 1b data for ORIC-533 in patients with multiple myeloma to be presented at the 65th ASH Annual Meeting being held December 9-12, 2023 Initial Phase 1b data for ORIC-944 in patients with prostate cancer expected in first quarter of 2024 Cash and investments of $256.2 million expected to fund operating plan into late 2025 SOUTH SAN FRANCISCO a |
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. Indeed, ORIC Pharmaceuticals... |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 1, 2023 (the “Grant Date”), ORIC granted a total of 14,800 non-qualified stock options and 2,480 restricted stock units to one new non-executive employee who began their employment with ORIC in October 2023. These inducement grant |
ORIC Price Returns
| 1-mo | 16.81% |
| 3-mo | N/A |
| 6-mo | 50.09% |
| 1-year | 96.90% |
| 3-year | -76.81% |
| 5-year | N/A |
| YTD | 40.41% |
| 2022 | -59.93% |
| 2021 | -56.57% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...